High incidence of vancomycin-associated leucopenia and neutropenia in a cardiothoracic surgical unit.
A retrospective case record review was undertaken to determine the incidence of vancomycin-associated leucopenia in a cardiothoracic surgical unit. Forty-nine patients received 50 courses of vancomycin therapy. Nine patients (18%) developed reversible leucopenia (white cell count less than 4000 x 10(6)/l) or neutropenia (polymorphonuclear leucocyte count less than 1500 x 10(6)/l). Four patients (8%) had severe neutropenia (less than 1000 x 10(6)/l). The median total dosage associated with leucopenia and neutropenia was 30 g, range 22-56 g. The median duration of treatment in leucopenic and neutropenic patients was 22 days, range 6-28 days. The median recovery time to a normal white cell count was 4 days, range 1-11 days. Patients who developed leucopenia on vancomycin therapy did not differ from those who did not with respect to age, total vancomycin dose, length of therapy, underlying illness, incidence of cardiac surgery or use of concomitant medications. Vancomycin-associated leucopenia and neutropenia is common in patients with cardiothoracic infections, many of whom are on several other medications. White cell counts should be estimated regularly in such patients.
Morris
A
A
Department of Microbiology, Green Lane Hospital, Auckland, New Zealand.
Ward
C
C
D000328:Adult; D000368:Aged; D003325:Coronary Care Units; D005260:Female; D006801:Humans; D015994:Incidence; D007970:Leukopenia / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced* / Q000453:epidemiology; D009873:Operating Rooms; D012189:Retrospective Studies; D013997:Time Factors; D014640:Vancomycin / Q000009:adverse effects*
D014640:Vancomycin